Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is approximately 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present consensus among 11 TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price goal of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment includes offering of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, which includes medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.